New 2023 Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplants for patients with Hodgkin lymphoma: a comparative study of the LWP EBMT.: GVHD prophylaxis for patients with Hodgkin lymphoma Group Lymphoma Working Party (LWP) 1st listed author J Montoro Journal Transplant Cell Ther.
New 2023 JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study Group Inborn Errors Working Party (IEWP) Other society 1st listed author Marco Fischer Journal J Allergy Clin Immunol.
New 2023 Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party Group Acute Leukemia Working Party (ALWP) 1st listed author Jesús Duque-Afonso Journal Bone Marrow Transplant.
New 2023 Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Marie Robin Journal Br J Haematol.
New 2023 Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Alicia Rovó Journal Am J Hematol.
New 2023 Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study Group Transplant Complications Working Party (TCWP) 1st listed author A Mussetti Journal Bone Marrow Transplant.
New 2023 Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation Group Infectious Diseases Working Party (IDWP) 1st listed author Christine Robin Journal Transplant Cell Ther.
New 2023 Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author V Potter Journal Bone Marrow Transplant.
2023 Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey Group Pharmacist Committee 1st listed author Nick Duncan Journal Bone Marrow Transplant.
2023 Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Rémy Duléry Journal Bone Marrow Transplant.
2023 Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Carmelo Gurnari Journal Lancet Haematol.
2023 Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT Group Infectious Diseases Working Party (IDWP) 1st listed author Jan Styczynski Journal Bone Marrow Transplant.